EpicGenetics continues to grow, processing more than 30,000 patient test appliciations and collaborating with additional research partners. The Mayo Clinic enters an agreement with EpicGenetics to document the ability of the FM/a® Test to expedite the diagnosis of fibromyalgia. Research begins with the University of Illinois College of Medicine at Chicago to study COVID-19 risks [...]
EpicGenetics moves from 3,716 sq. foot facility to new 11,800 square foot facility.
EpicGenetics and Harvard/Massachusetts General Hospital receive FDA approval for a Phase II clinical trial to test a potential fibromyalgia treatment. The research will explore a treatment that will permanently reverse the symptoms of the disease. Scheduled to begin in 2022.
Research begins on a Genomics study at The University of Illinois College of Medicine at Chicago. The study investigates whether there is a genetic component to fibromyalgia. Results are scheduled to be submitted for review in 2021.
